New Hampshire Trust Sells 32 Shares of Eli Lilly and Company (NYSE:LLY)

New Hampshire Trust trimmed its position in shares of Eli Lilly and Company (NYSE:LLY) by 4.6% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 668 shares of the company’s stock after selling 32 shares during the quarter. New Hampshire Trust’s holdings in Eli Lilly and Company were worth $552,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Elevate Capital Advisors LLC purchased a new stake in Eli Lilly and Company during the fourth quarter valued at $262,000. Capital & Planning LLC grew its position in shares of Eli Lilly and Company by 15.6% during the fourth quarter. Capital & Planning LLC now owns 481 shares of the company’s stock worth $371,000 after purchasing an additional 65 shares in the last quarter. Garner Asset Management Corp grew its position in shares of Eli Lilly and Company by 2.3% during the fourth quarter. Garner Asset Management Corp now owns 532 shares of the company’s stock worth $411,000 after purchasing an additional 12 shares in the last quarter. Brighton Jones LLC grew its position in shares of Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after purchasing an additional 1,730 shares in the last quarter. Finally, Union Bancaire Privee UBP SA purchased a new stake in shares of Eli Lilly and Company during the fourth quarter worth about $49,534,000. 82.53% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the business’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the transaction, the chief accounting officer now owns 5,840 shares in the company, valued at approximately $4,778,521.60. The trade was a 14.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Up 2.2%

Shares of NYSE:LLY opened at $738.33 on Friday. The company has a 50 day moving average price of $776.85 and a 200 day moving average price of $799.96. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The stock has a market capitalization of $699.74 billion, a price-to-earnings ratio of 63.05, a PEG ratio of 1.40 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). The company had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The company’s quarterly revenue was up 45.2% on a year-over-year basis. During the same period last year, the business earned $2.58 EPS. On average, research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be issued a $1.50 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $6.00 annualized dividend and a yield of 0.81%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 48.82%.

Wall Street Analyst Weigh In

LLY has been the subject of several analyst reports. Hsbc Global Res lowered Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research note on Monday, April 28th. Wells Fargo & Company restated an “overweight” rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Morgan Stanley reiterated an “overweight” rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Wall Street Zen raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday. Finally, Truist Financial increased their price target on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a report on Monday, February 3rd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average price target of $1,011.37.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.